Conversant Bio was founded in 2006 because the drug discovery research model was broken.
It simply takes too long for drugs to get to patients, there are too many failures late in development, and the entire process costs too much. The lack of well-characterized, appropriately consented human biospecimens continues to hamper the development of new drugs. Seeking to fix this process, Conversant Bio addresses these problems in a new way.
From day one, we’ve had one mantra guide us:Because Patients Are Waiting… ™